• Serves as program manager for research and global program teams• Supports the development and implementation of research and development plans• Aligns cross-functional program goals with Sarepta’s R&D and corporate goals• For external partnerships, ensures that the internal Sarepta deliverables are executed, tracked, and communicated to key stakeholders• Collaborates with external partners to ensure timely execution of Sarepta's key priorities and deliverables• Guides and independently manages development of presentations for different teams (internal or external)

• Serves as program manager for research and global program teams• Supports the development and implementation of research and development plans• Aligns cross-functional program goals with Sarepta’s R&D and corporate goals• For external programs, ensures that the internal Sarepta deliverables are executed, tracked, and communicated to key stakeholders• Guides and independently manages development of presentations for different teams (internal or external)• Collaborates with cross-functional team members to facilitate a smooth transition from research to development

• Designed and executed preclinical proof of concept studies to identify new indication opportunities for both preclinical and clinical assets• Drove IND enabling studies for preclinical programs• Identified and managed external research relationships (CROs, academic collaborators)• Operationalized and managed the data flow from multiple external partners• Generated data packages for publications and regulatory submissions• Prepared, reviewed and delivered high quality scientific reports and presentations for internal and external use

• Conducted cellular and molecular experiments to support technology platform• Led therapeutic programs in colitis and AAV, and assisted in multiple sclerosis and celiac disease programs• Designed, optimized and established an in vitro system using human peripheral blood mononuclear cells to assess immunological processes following treatment with lead therapeutic candidates• Established in vivo preclinical models to investigate therapeutic efficacy of lead candidates• Analyzed and interpreted data and communicated results to preclinical team• Facilitated and coordinated with CROs in execution of desired studies• Developed and wrote grant proposals to government organizations• Prepared and delivered a presentation to pitch technology platform to potential external partners• Collaborated with and drafted research proposals for external key stakeholders

Advisor: Kevin D. Niswender, M.D., Ph.D.• Led and conducted genetic, cellular and molecular experiments to investigate human variants of the glucagon-like peptide-1 receptor (GLP-1R) provide protection against diabetes and cardiovascular disease• Generated and edited vector constructs and engineered them into human cell lines• Designed, optimized, and performed in vitro pharmacological assays to assess how the GLP-1R variants alter receptor coupling to downstream signaling pathways using reporter genes, fluorescence and ELISA assays• Co-led project and studies focusing on discovering positive allosteric modulators (PAMs) of GLP-1R for pharmaceutical potential utilizing Functional Drug Screening System through collaboration with medicinal chemists in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD)• Operated and maintained high-throughput automated screening equipment• Collaborate with investigators in the Vanderbilt Division of Allergy, Pulmonary, and Critical Care Medicine on defining a novel mechanism by which GLP-1R activity downregulates immune responses to allergens in the setting of obesity• Developed and performed in vitro assays to assess GLP-1R activity in human and mouse bronchial epithelial cells by transient transfections, reporter gene and fluorescence assays• Participated in preparing and writing grant applications

Ph.D. in Pathobiology and Molecular MedicineAdvisor: Stephen D. Zucker, M.D.• Led and conducted cellular and molecular studies to investigate the role of VCAM-1 and ICAM-1 in the pathogenesis of atherosclerosis and ulcerative colitis and, to elucidate the molecular mechanisms underlying the protective effect of bilirubin• Successfully established an in vitro system that mimics adhesion to and migration of monocytes and lymphocytes across isolated human endothelial cells• Utilized in vivo mouse models to understand the physiological and pathophysiological roles of VCAM-1 and ICAM-1• Collaborated to publish 3 peer-reviewed manuscripts• Invited to present formal seminars and several posters at departmental, regional and national conferences

Project title: Opportunistic Fungal and Bacterial Pathogens Measured by Quantitative PCR in Source and Finished WaterAdvisor: Stephen Vesper, Ph.D.The objective of this project was to test water samples from various drinking water treatment plants across the United States for several species of fungi and bacteria.Author on the published manuscript "Microbial pathogens in source and treated waters from drinking water treatment plants in the United States and implications for human health"

Advisor: Kelly McCall, Ph.D.• Maintained mouse colonies, administered drug treatments to mice, performed glucose tolerance tests, collected and analyzed metabolic parameters, and prepared tissue samples for immunohistochemistry• Trained rotating medical students in lab techniques• Attended and participated in weekly lab meetings and journal clubs and, monthly diabetes research seminars• Presented research results at local conference and won first place for poster presentation

Advisor: Stephen C. Bergmeier, Ph.D.The objective of this project was to synthesize various analogs of the fused oxazolidinone-piperazine compound with diverse side-chains for antiviral and antibacterial actions. Co-author of published manuscript "Fused Ring Aziridines as a Facile Entry into Triazole Fused Tricyclic and Bicyclic Heterocycles"